0
Signin
countryflagUS

18889881171

MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%

Pieris Pharmaceuticals Inc

Healthcare US PIRS

17.2USD
2.15(14.29%)

Last update at 2024-07-25T16:55:00Z

Day Range

14.2518.20
LowHigh

52 Week Range

9.6680.80
LowHigh

Fundamentals

  • Previous Close 15.05
  • Market Cap13.84M
  • Volume253280
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.94000M
  • Revenue TTM42.81M
  • Revenue Per Share TTM38.03
  • Gross Profit TTM -27.08000M
  • Diluted EPS TTM-11.4

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -33.27700M -45.73800M -37.06600M -25.46900M -27.06600M
Minority interest - - - - -
Net income -31.25300M -43.36600M -37.23000M -23.75500M -26.75400M
Selling general administrative 16.39M 16.59M 16.71M 18.44M 18.44M
Selling and marketing expenses - - - - -
Gross profit 25.90M 31.42M 29.32M 46.28M 29.10M
Reconciled depreciation 2.78M 2.37M 2.13M 1.04M 0.57M
Ebit -43.47400M -51.83100M -33.92100M -27.15700M -30.83100M
Ebitda -35.30100M -48.14600M -31.79400M -26.11700M -30.26100M
Depreciation and amortization 8.17M 3.69M 2.13M 1.04M 0.57M
Non operating income net other - 2.40M -3.65600M -0.02600M 1.80M
Operating income -43.47400M -51.83100M -33.92100M -27.15700M -30.83100M
Other operating expenses 61.20M 79.56M 63.24M 73.44M 59.93M
Interest expense -10.19700M 6.09M 3.15M 1.69M 3.77M
Tax provision - 0.00000M 0.16M 0.00000M -0.31200M
Interest income 0.72M 0.00400M 0.51M 1.71M 1.96M
Net interest income 0.72M 0.00400M 0.51M 1.71M 1.96M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.02400M -2.37200M 0.16M -1.71400M -0.31200M
Total revenue 25.90M 31.42M 29.32M 46.28M 29.10M
Total operating expenses 61.20M 79.56M 63.24M 73.44M 59.93M
Cost of revenue - - - - 0.00000M
Total other income expense net 10.20M 6.09M -3.14500M 1.69M 3.77M
Discontinued operations - - - - -
Net income from continuing ops -33.27700M -45.73800M -37.23000M -25.46900M -26.75400M
Net income applicable to common shares - -45.73800M -37.23000M -28.29900M -26.75400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 38.68M 95.49M 153.56M 105.01M 141.10M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.28M 8.45M 6.55M 3.58M 4.07M
Total liab 11.92M 67.56M 102.81M 73.98M 89.75M
Total stockholder equity 26.76M 27.93M 50.76M 31.03M 51.35M
Deferred long term liab - - - - -
Other current liab 8.55M 10.75M 15.79M 5.48M 4.96M
Common stock 0.10M 0.07M 0.07M 0.06M 0.06M
Capital stock - 0.07M 0.07M 0.06M 0.06M
Retained earnings -314.96400M -290.42100M -257.14400M -211.40600M -174.17600M
Other liab - 18.73M 38.40M 35.91M 47.26M
Good will - - - - -
Other assets - - 2.90M 7.24M 3.15M
Cash 17.40M 38.63M 117.76M 70.44M 62.26M
Cash and equivalents - - - - -
Total current liabilities 11.92M 36.58M 50.56M 22.14M 27.00M
Current deferred revenue - 20.82M 25.12M 12.63M 11.26M
Net debt -17.39600M -25.53200M -103.92300M -53.47400M -46.04300M
Short term debt - 0.86M 1.05M 1.03M 0.73M
Short long term debt - - - - -
Short long term debt total - 13.10M 13.84M 16.96M 16.22M
Other stockholder equity 341.60M 318.53M 307.00M 242.67M 227.47M
Property plant equipment - 20.70M 23.03M 25.98M 19.50M
Total current assets 38.68M 73.42M 127.62M 75.72M 115.01M
Long term investments - - - - -
Net tangible assets - 27.93M 50.76M 31.03M 51.35M
Short term investments 8.97M 20.53M 0.00000M 0.00000M 41.89M
Net receivables 6.04M 5.81M 3.31M 1.71M 6.79M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 3.37M 4.15M 8.61M 3.01M 10.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.03M -0.25400M 0.83M -0.29500M -1.99500M
Additional paid in capital - - - - -
Common stock total equity - - 0.07M 0.06M 0.06M
Preferred stock total equity - - - - -
Retained earnings total equity - - -257.14400M -211.40600M -174.17600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 1.37M 2.90M 3.31M 3.15M
Deferred long term asset charges - - - - -
Non current assets total - 22.07M 25.93M 29.29M 26.08M
Capital lease obligations - 13.10M 14.89M 16.96M 16.22M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -21.23600M -0.94900M 41.94M 12.30M -7.17700M
Change to liabilities - 36.48M -18.85000M -28.18100M 13.32M
Total cashflows from investing activities - -0.94900M 39.21M 9.84M -8.87500M
Net borrowings - - - - -
Total cash from financing activities 7.21M 59.13M 10.12M 32.17M 48.51M
Change to operating activities - 5.73M -2.87000M -0.79900M -0.69000M
Net income -33.27700M -45.73800M -37.23000M -25.46900M -26.75400M
Change in cash -79.12900M 47.33M 8.18M -12.60700M 36.99M
Begin period cash flow 117.76M 70.44M 62.26M 74.87M 37.88M
End period cash flow 38.63M 117.76M 70.44M 62.26M 74.87M
Total cash from operating activities -59.93200M -7.66000M -45.89600M -52.46700M -1.06600M
Issuance of capital stock 6.92M 57.10M 9.62M 31.00M 47.21M
Depreciation 2.78M 2.37M 2.13M 1.04M 0.57M
Other cashflows from investing activities - - - 12.30M -7.17700M
Dividends paid - - - - -
Change to inventory - 5.73M -2.87000M -0.79900M -
Change to account receivables -2.62400M -1.81300M 5.34M -4.05500M 12.51M
Sale purchase of stock - 59.13M 10.12M 32.21M 48.51M
Other cashflows from financing activities 0.29M 2.03M 0.49M 1.17M 1.30M
Change to netincome - 5.18M 5.40M 4.08M 3.23M
Capital expenditures 1.04M 0.95M 2.73M 2.46M 1.70M
Change receivables - -1.81300M 5.34M -4.05500M 12.51M
Cash flows other operating - -4.23300M -1.39900M 0.52M -3.93900M
Exchange rate changes - - - - -1.58100M
Cash and cash equivalents changes - 50.52M 3.43M -10.46300M 36.99M
Change in working capital -33.37000M 30.52M -16.37700M -32.12100M 21.89M
Stock based compensation 4.40M 5.21M 5.09M 5.37M 4.94M
Other non cash items -0.46700M -0.03000M 0.33M -0.06900M -1.55400M
Free cash flow -60.97300M -8.60900M -48.62200M -54.92900M -2.76400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PIRS
Pieris Pharmaceuticals Inc		 2.15 14.29% 17.20 - - 0.40 0.64 0.59 0.90
NVO
Novo Nordisk A/S		 -2.29 1.74% 129.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.80 2.90% 135.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.67 0.75% 494.48 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 22.92 2.16% 1083.78 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Pieris Pharmaceuticals Inc

225 Franklin Street, Boston, MA, United States, 02110

Key Executives

Name Title Year Born
Mr. Stephen S. Yoder J.D. CEO, Pres & Director 1976
Dr. Hitto Kaufmann Ph.D. Sr. VP & Chief Scientific Officer 1971
Mr. Thomas Bures Sr. VP & CFO 1974
Maria Kelman Exec. Director of Investor Relations NA
Mr. Ahmed S. Mousa J.D. Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec. 1985
Mr. Frank Vollmering VP of HR NA
Dr. Christine Rothe Ph.D. VP and Head of Early Stage Project Leadership & Data Science NA
Dr. Shane Olwill Ph.D. Sr. VP & Chief Devel. Officer 1976
Mr. Prompong Chaikul Chief Supply Chain Officer 1987
Dr. Gordon Otto M.D., Ph.D. Head of Clinical Devel. Oncology NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.